Universitätsklinikum Magdeburg, Klinik für Radiologie & Nuklearmedizin, Magdeburg, Germany.
Cardiovasc Intervent Radiol. 2012 Oct;35(5):1066-73. doi: 10.1007/s00270-011-0234-7. Epub 2011 Jul 29.
This study was designed to evaluate overall survival after radioembolization or best supportive care (BSC) in patients with chemotherapy-refractory liver-dominant metastatic colorectal cancer (mCRC).
This was a matched-pair comparison of patients who received radioembolization plus BSC or BSC alone for extensive liver disease. Twenty-nine patients who received radioembolization were retrospectively matched with a contemporary cohort of >500 patients who received BSC from 3 centers in Germany. Using clinical databases, patients were initially matched for prior treatments and tumor burden and then 29 patients were consecutively identified with two or more of four matching criteria: synchronous/metachronous metastases, tumor burden, increased ALP, and/or CEA >200 U/ml. Survival was calculated from date of progression before radioembolization or BSC by using Kaplan-Meier analysis.
Of 29 patients in each study arm, 16 pairs (55.2%) matched for all four criteria, and 11 pairs (37.9%) matched three criteria. Patients in both groups had a similar performance status (Karnofsky index, median 80% [range, 60-100%]). Compared with BSC alone, radioembolization prolonged survival (median, 8.3 vs. 3.5 months; P < 0.001) with a hazard ratio of 0.3 (95% confidence interval, 0.16-0.55; P < 0.001) in a multivariate Cox proportional hazard model. Treatment-related adverse events following radioembolization included: grade 1-2 fatigue (n = 20, 69%), grade 1 abdominal pain/nausea (n = 14, 48.3%), and grade 2 gastrointestinal ulceration (n = 3, 10.3%). Three cases of grade 3 radiation-induced liver disease were symptomatically managed.
Radioembolization offers a promising addition to BSC in treatment-refractory patients for whom there are limited options. Survival was prolonged and adverse events were generally mild-to-moderate in nature and manageable.
本研究旨在评估化疗耐药肝转移结直肠癌(mCRC)患者接受放射性栓塞术或最佳支持治疗(BSC)后的总生存期。
这是一项接受放射性栓塞术联合 BSC 或单独 BSC 治疗广泛肝疾病的患者配对比较研究。29 例接受放射性栓塞术的患者与来自德国 3 个中心的>500 例接受 BSC 的同期队列患者进行了回顾性配对。通过临床数据库,患者首先根据先前的治疗和肿瘤负担进行匹配,然后连续确定 29 例符合以下 4 个匹配标准中的 2 个或更多标准的患者:同步/异时转移、肿瘤负担、碱性磷酸酶升高和/或癌胚抗原>200 U/ml。采用 Kaplan-Meier 分析计算从放射性栓塞术或 BSC 前进展开始的生存时间。
在每个研究组的 29 例患者中,16 对(55.2%)按所有 4 个标准匹配,11 对(37.9%)按 3 个标准匹配。两组患者的一般状态(Karnofsky 指数,中位数 80%[范围,60%-100%])相似。与单独 BSC 相比,放射性栓塞术延长了生存期(中位数 8.3 个月 vs. 3.5 个月;P<0.001),多变量 Cox 比例风险模型显示,风险比为 0.3(95%置信区间,0.16-0.55;P<0.001)。放射性栓塞术相关的不良反应包括:1-2 级疲劳(n=20,69%)、1 级腹痛/恶心(n=14,48.3%)和 2 级胃肠道溃疡(n=3,10.3%)。3 例 3 级放射性肝损伤症状性管理。
对于治疗耐药且选择有限的患者,放射性栓塞术是 BSC 的一种很有前途的治疗方法。生存时间延长,不良反应通常为轻至中度,且可管理。